Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 65

Sort by

Sort Order Select

Journal Articles

Somatic TET2 Mutations Prime the Immune System for Response to Immune Checkpoint Blockade

Robert Vanner, Andy G.X. Zeng, Michelle Chan-Seng-Yue, Suraj Bansal, Elisa Donato, Liqing Jin, Sofia Genta, Enrique Sanz Garcia, Steven M. Chan, Andreas Trumpp, John E. Dick

Blood (2023) 142 (Supplement 1): 2689.

https://doi.org/10.1182/blood-2023-177740

Published: 2023

Journal Articles

Uncovering the Role of CD59 As a Novel Therapeutic Target Against High-Risk Acute Myeloid Leukemia

Abdula Maher, Steven M. Chan

Blood (2023) 142 (Supplement 1): 1376.

https://doi.org/10.1182/blood-2023-191036

Published: 2023

Journal Articles

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Josephine Anne Lucero, Aniket Bankar, Marta Beata Davidson, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Dawn C. Maze, Karen Yee, Mark D. Minden, Steven M. Chan, Jonas Mattsson, Rajat Kumar, Vikas Gupta, Jose-Mario Capo-Chichi, Tracy Stockley, Hassan Sibai, Anne Maria Tierens, Dennis Dong Hwan Kim

Blood (2023) 142 (Supplement 1): 1595.

https://doi.org/10.1182/blood-2023-190694

Published: 2023

Journal Articles

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Guillaume Richard-Carpentier, Gopila Gupta, Charina Cameron, Severine Cathelin, Aniket Bankar, Marta Beata Davidson, Vikas Gupta, Dawn C. Maze, Mark D. Minden, Tracy Murphy, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Joseph Brandwein, Caroline Jane McNamara, Steven M. Chan

Blood (2023) 142 (Supplement 1): 159.

https://doi.org/10.1182/blood-2023-188341

Published: 2023

Journal Articles

Clinical Outcomes in De Novo Versus Secondary NPM1 -Mutated AML

Elliot C. Smith, Eshetu G. Atenafu, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Dawn Maze

Blood (2022) 140 (Supplement 1): 8952–8953.

https://doi.org/10.1182/blood-2022-166939

Published: 2022

Journal Articles

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Maria Agustina Perusini, Eshetu G. Atenafu, Aniket Bankar, Vikas Gupta, Mark D. Minden, Jad Sibai, Dawn Maze, Marta B. Davidson, Steven M. Chan, Fernando Binder, Guillaume Richard-Carpentier, Salman Alharbi, Claire Andrews, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3176–3177.

https://doi.org/10.1182/blood-2022-170121

Published: 2022

Journal Articles

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

Fatima M Khadadah, Claire Andrews, Eshetu G. Atenafu, Andre C. Schuh, Dawn Maze, Karen Yee, Osamah Jamal S. Jarallah, Mark D. Minden, Aaron D. Schimmer, Steven M. Chan, Vikas Gupta, Dennis Dong Hwan Kim, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3169–3171.

https://doi.org/10.1182/blood-2022-169342

Published: 2022

Journal Articles

A Novel Role for PLK1 in Leukemia Stem Cell Function in Acute Myeloid Leukemia

Qiang Liu, Alex Murison, Andy G.X. Zeng, Changjiang Xu, Veronique Voisin, Faith Yeung, Amit Subedi, Steven M. Chan, Brian Raught, Gary D Bader, John E. Dick, Jean C.Y. Wang

Blood (2022) 140 (Supplement 1): 5920–5921.

https://doi.org/10.1182/blood-2022-169732

Published: 2022

Journal Articles

Uncovering Distinct Metabolic Properties of Relapse and Relapse-Fated Clones in B-Cell Acute Lymphoblastic Leukemia

Sabrina A Smith, Laura Garcia Prat, Mohsen Hosseini, Liqing Jin, Nathan Mbong, Monica Doedens, Jessica McLeod, Julie A. Reisz, Rebecca Wilkerson, Angelo D'Alessandro, Steven M. Chan, Courtney L Jones, John E. Dick

Blood (2022) 140 (Supplement 1): 5905–5906.

https://doi.org/10.1182/blood-2022-162652

Published: 2022

Journal Articles

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Kenny Tang, Dawn Maze, Karen Yee, Hassan Sibai, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Andre C. Schuh, Aniket Bankar, Guillaume Richard-Carpentier, Anne Tierens, Mark D. Minden, Vikas Gupta, Jeffrey H. Lipton, Dennis Kim

Blood (2022) 140 (Supplement 1): 9608–9610.

https://doi.org/10.1182/blood-2022-166416

Published: 2022

Journal Articles

Multiparameter Flow Cytometry-Based Residual Disease Analysis Identifies Intermediate-Risk AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Josephine Anne Lucero, Anne Tierens, Muhned Alhumaid, Jose-Mario Capo-Chichi, Tracy L. Stockley, Vikas Gupta, Steven M. Chan, Andre C. Schuh, Mark D. Minden, Jonas Mattsson, Rajat Kumar, Hassan Sibai, Dennis Dong Hwan Kim

Blood (2022) 140 (Supplement 1): 11797–11798.

https://doi.org/10.1182/blood-2022-168260

Published: 2022

Journal Articles

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Maria Agustina Perusini, Jad Sibai, Eshetu G. Atenafu, Aniket Bankar, Mark D. Minden, Vikas Gupta, Dawn Maze, Marta B. Davidson, Steven M. Chan, Aaron D. Schimmer, Guillaume Richard-Carpentier, Josephine Anne Lucero, Claire Andrews, Dennis Dong Hwan Kim, Karen Yee, Andre C. Schuh, Hassan Sibai

Blood (2022) 140 (Supplement 1): 6039–6041.

https://doi.org/10.1182/blood-2022-169406

Published: 2022

Journal Articles

Thrombopoietin Receptor Signaling Promotes the Competitive Advantage of TET2 -Mutated Hematopoietic Stem and Progenitor Cells in Clonal Hematopoiesis

Yitong Yang, Amit Subedi, Steven M. Chan

Blood (2022) 140 (Supplement 1): 981–982.

https://doi.org/10.1182/blood-2022-162554

Published: 2022

Journal Articles

Metformin Treatment Abrogates the Competitive Advantage of Dnmt3a R878H HSPCs By Enhancing DNA Methylation Activity

Mohsen Hosseini, Severine Cathelin, Alex Liu, Yitong Yang, Amit Subedi, Dhanoop Manikoth Ayyathan, Shraddha Pai, Steven M. Chan

Blood (2022) 140 (Supplement 1): 977–978.

https://doi.org/10.1182/blood-2022-170366

Published: 2022

Journal Articles

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Josephine Anne Lucero, Brayan Merchán, Osamah Jamal S. Jarallah, Aniket Bankar, Steven M. Chan, Marta B. Davidson, Vikas Gupta, Dawn Maze, Mark D. Minden, Guillaume Richard-Carpentier, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3166–3168.

https://doi.org/10.1182/blood-2022-168488

Published: 2022

Journal Articles

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

Salman Alharbi, Maria Agustina Perusini, Sita Bhella, Mark D. Minden, Dawn Maze, Vikas Gupta, Aaron D. Schimmer, Andre C. Schuh, Karen Yee, Steven M. Chan, Aniket Bankar, Marta B. Davidson, Guillaume Richard-Carpentier, Jad Sibai, Hassan Sibai

Blood (2022) 140 (Supplement 1): 3187–3188.

https://doi.org/10.1182/blood-2022-168662

Published: 2022

Journal Articles

STAT5 Signaling Promotes Resistance to Ivosidenib in IDH1 -Mutated AML

Alex Liu, Severine Cathelin, Steven M Chan

Blood (2021) 138 (Supplement 1): 210.

https://doi.org/10.1182/blood-2021-154278

Published: 2021

Journal Articles

Inhibition of PINK1-Dependent Mitochondrial Quality Control Pathways Induces Senescence of Acute Myeloid Leukemia Stem Cells

Dhanoop Manikoth Ayyathan, David Sharon, Severine Cathelin, Steven M Chan

Blood (2021) 138 (Supplement 1): 2225.

https://doi.org/10.1182/blood-2021-153847

Published: 2021

Journal Articles

Enasidenib in Combination with Venetoclax in IDH2 -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial

Steven M Chan, Charina Cameron, Severine Cathelin, Vikas Gupta, Dawn Maze, Mark D. Minden, Tracy Murphy, Aaron D Schimmer, Andre C. Schuh, Hassan Sibai, Karen Yee, Courtney D. DiNardo, Caroline J McNamara

Blood (2021) 138 (Supplement 1): 1263.

https://doi.org/10.1182/blood-2021-153660

Published: 2021

Journal Articles

Inhibition of the DOT1L/MPL/JAK2 Signaling Axis Selectively Targets TET2 Mutation-Driven Clonal Hematopoiesis

Yitong Yang, Amit Subedi, Steven M Chan

Blood (2021) 138 (Supplement 1): 3281.

https://doi.org/10.1182/blood-2021-153240

Published: 2021

NARROW

Somatic TET2 Mutations Prime the Immune System for Response to Immune Checkpoint Blockade

Uncovering the Role of CD59 As a Novel Therapeutic Target Against High-Risk Acute Myeloid Leukemia

Prognostic Role of Multiparameter Flow Cytometry-Based Measurable Residual Disease Assessment in Acute Myeloid Leukemia Patients with FMS3-like Tyrosine Kinase-3 Internal Tandem Duplication (FLT3-ITD)

Final Results of the Phase Ib/II Study Evaluating Enasidenib in Combination with Venetoclax in Patients with IDH2 -Mutated Relapsed/Refractory Myeloid Malignancies

Clinical Outcomes in De Novo Versus Secondary NPM1 -Mutated AML

Acute Lymphoblastic Leukemia in Patients 60 Years and Older Treated with Pediatric-Inspired Protocols, 20 Years of Follow-up

Do Adult Philadelphia-Positive Acute Lymphoblastic Leukemia (Ph+ ALL) Patients Require Allogeneic Transplant in First Remission (CR1)?

A Novel Role for PLK1 in Leukemia Stem Cell Function in Acute Myeloid Leukemia

Uncovering Distinct Metabolic Properties of Relapse and Relapse-Fated Clones in B-Cell Acute Lymphoblastic Leukemia

Single Centre, Retrospective Analysis of Treatment Outcomes and Prognostic Factors in Blastic Phase Chronic Myeloid Leukemia (CML-BP) Following Systemic Therapy

Multiparameter Flow Cytometry-Based Residual Disease Analysis Identifies Intermediate-Risk AML Patients Who May Benefit from Allogeneic Hematopoietic Stem Cell Transplantation

Real-World Outcomes and Adverse Events of Elderly Patients with Ph-Negative Acute Lymphoblastic Leukemia Treated with a Pediatric-Inspired Protocol

Thrombopoietin Receptor Signaling Promotes the Competitive Advantage of TET2 -Mutated Hematopoietic Stem and Progenitor Cells in Clonal Hematopoiesis

Metformin Treatment Abrogates the Competitive Advantage of Dnmt3a R878H HSPCs By Enhancing DNA Methylation Activity

Clinical and Biological Characteristics and Outcomes of Therapy-Related Acute Lymphoblastic Leukemia (t-ALL) Following Multiple Myeloma Are Distinct in Comparison to t-ALL Following Other Cancers

Outcome of ALL in Adult Patient with Down Syndrome, Single Center Experience

STAT5 Signaling Promotes Resistance to Ivosidenib in IDH1 -Mutated AML

Inhibition of PINK1-Dependent Mitochondrial Quality Control Pathways Induces Senescence of Acute Myeloid Leukemia Stem Cells

Enasidenib in Combination with Venetoclax in IDH2 -Mutated Myeloid Malignancies: Preliminary Results of the Phase Ib/II Enaven-AML Trial

Inhibition of the DOT1L/MPL/JAK2 Signaling Axis Selectively Targets TET2 Mutation-Driven Clonal Hematopoiesis

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only